$0.88

-0.03 (-3.39%)
Live
Previous Close

$0.902

Day Range

$0.8754 - $0.9399

Previous Day Range

$0.8723 - $0.9387

Market Cap

$57.3 million USD

Day Vol.

72590

Previous Day Vol.

52450

Currency

USD

Primary Exchange

Nasdaq

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber,...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

CytoSorbents reported a 3% decrease in Q1 2025 revenue, but improved operating loss and net loss. The company is making progress with its DrugSorb-ATR device, which is under review by the FDA and Health Canada.

Related tickers: CTSO.

Read Full Article

CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in CABG patients on the antiplatelet drug Brilinta. The company plans to continue working with the FDA to resolve the remaining issues and obtain regulatory approval.

Related tickers: CTSO.

Read Full Article
Trending Tickers

Please sign in to view